OKYO Pharma Ltd. (OKYO) is scheduled to present an update on the development of its lead drug candidate, Urcosimod, for the treatment of neuropathic corneal pain at the BIO International Convention, taking place from June 16 to 19, 2025.
Neuropathic corneal pain is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of neuropathic corneal pain is unknown, but it is thought to result from nerve damage to the cornea combined with inflammation. Currently, there are no FDA-approved drugs to treat this condition.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com